1Keck Jr PE, McElroy SL, Richtand N, et al. What makes a drug a primary mood stabilizer ? Mol Psychiatry, 2002,7 ( suppl 1 ) : S8.
2Bowden CL, Lecrubier Y, Bauer M, et al. Maintenance therapies for classic and other forms of bipolar disorder. J Affect Disord, 2000,59 ( suppl 1) :S57.
3Alao AO. The frontier of mood stabilizers in psychiatry. Psychiatric Times, 2002 : 6.
4Alao AO, Dewan MJ. Evaluating the tolerability of the newer mood stabilizers.J Nerv Ment Dis,2001,189:60.
5Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry, 2001,50: 898.
6Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am, 1997,20:427.
7Bschor T, Canata B, Muller-Oerlinghausen B, et al. Predictors of response to lithium augmentation in tRicyclic antidepressant-resistant depression. J Affect Disord,2001,64:261.
8Davis LL, Byan W, Adinoff B, et al. Comprehensive review of the psychiatric uses of valproate.j Clin Psychopharmacol, 2000,20( suppl 1 ) : 1S.
9Wroblewski BA, Joseph AB, Kupfer J, et al. Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired braininjury. Brain Inj, 1997,11 : 37.
10Hollander E. Managing aggressive behavior in patients with obsessivecompulsive disorder and borderline personality disorder. J Clin Psychiatry, 1999,60(suppl 15) :38.
9Keck P E Jr. Evaluation and Management of Breakthrough Depressive Episode[J]. J Clin Psychiatry, 2004, 64(suppl10):11-15.
10Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry Task Force on Treatment GuideLines for Bipolar Disorders. World Federation of Societies of Biological Psychiatry(WFSBP) guidelines for biological treatment of bipolar disorders[J]. World J Biol Psychiatry, 2002,3(3): 115- 124.
